ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Viral Live-Attenuated Vaccines (LAVs): Past and Future Directions.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Recent advances on coxsackievirus A6 vaccine research.Frontiers in immunology · 2025Pooled it
- A novel cystic fibrosis-mimetic Pseudomonas auxotrophic vaccine is protective in vivo and is associated with IL-17/IgA mucosal Immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- A Humanized Anti-gD Broadly Neutralizing Antibody Confers Complete Post-Exposure Protection Against Pseudorabies Virus.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Smart nanoparticle vaccines integrate nanotechnology artificial intelligence and immunoengineering for precision immunization.Discover nano · 2026Review
- Recombinant Alphaherpesvirus Vectors in Veterinary Vaccinology: Platforms, Applications, and Translational Challenges.International journal of molecular sciences · 2026Review
- Live-Attenuated Vaccines Against African Swine Fever: Strategies, Lessons, and Prospects.Biology · 2026Review
- Live-attenuated Rift Valley fever virus vaccination leads to durable, protective immunity independent of sex in C57BL/6 mice.The Journal of infectious diseases · 2026Article
- Targeting the lethal weakness of SFTSV: Latest advances in antiviral strategies and immune prevention.iScience · 2026Review
- Accumulation of mutations in nsp4, E, and the S2 subunit underlies mammalian cell tropism expansion and virulence attenuation of avian coronavirus.PLoS pathogens · 2026Article
- Editorial: Molecular host-pathogen interactions in veterinary infectious diseases: from pathogenesis to immunomodulatory therapies.Frontiers in veterinary science · 2026Article
- Development and characterization of a monoclonal antibody against Pseudorabies virus glycoprotein B and its application in tracking viral infection.Frontiers in microbiology · 2026Article
- Comparison of efficacy, safety, immune response of dNS1 LAIV and cold-adapted LAIV in a mouse model.NPJ vaccines · 2025Article
- A glycoprotein D-targeted lipid nanoparticle-encapsulated mRNA vaccine elicits strong protective immunity against pseudorabies virus.Journal of virology · 2025Article
- Re-emergence of chikungunya virus in China by 2025: What we know and what to do?PLoS pathogens · 2025Review
- Nsp2 replicase-mediated viral uncoating in porcine alveolar macrophages contributes to the attenuation of PRRSV-2 live attenuated vaccine.Journal of virology · 2025Article
- Advances and Prospects of Fowl Adenoviruses Vaccine Technologies in the Past Decade.International journal of molecular sciences · 2025Review
- EIAV encodes an accessory protein that antagonizes the host restriction factor equine tetherin.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The neonatal Fc receptor (FcRn): Guardian or Trojan Horse in viral infection?PLoS pathogens · 2025Review
- Article
- Recent advances in the prevention and treatment of respiratory syncytial virus disease.The Journal of general virology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Viral infections continue to pose a significant threat to the health of both humans and animals. Currently, live attenuated vaccines (LAVs) remain the most efficacious and widely utilized tool for combating viral infections. Conventional LAVs involve the adaptation of virulent viruses to novel hosts, cell cultures, or suboptimal environments, resulting in a reduction in pathogenicity while retaining immunogenicity. This process entails directed evolution of the virus to enhance its replication efficiency under these modified conditions. In this review, the development of traditional animal-adapted and cold-adapted LAVs is specially discussed. Additionally, the factors that contribute to virus attenuation from a viral lifecycle perspective are summarized. Finally, we propose future directions for next-generation LAVs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.